2例白血病患者行嵌合抗原受体T细胞治疗合并严重神经毒性的护理

阮海涛, 张姿怡, 周丽, 徐丽

护理学报 ›› 2022, Vol. 29 ›› Issue (12) : 67-69.

PDF(450 KB)
PDF(450 KB)
护理学报 ›› 2022, Vol. 29 ›› Issue (12) : 67-69. DOI: 10.16460/j.issn1008-9969.2022.12.067
临床护理-内科护理

2例白血病患者行嵌合抗原受体T细胞治疗合并严重神经毒性的护理

  • 阮海涛, 张姿怡, 周丽, 徐丽
作者信息 +

Nursing of Leukemia Patients Undergoing Chimeric Antigen Receptor T-cell Therapy with Severe Neurotoxicity: A 2-case Study

  • RUAN Hai-tao, ZHANG Zi-yi, ZHOU Li, XU Li
Author information +
文章历史 +

摘要

目的 总结2例急性淋巴细胞白血病行嵌合抗原受体T细胞治疗合并严重免疫效应细胞相关神经毒性综合征患者的护理经验。方法 2例患者护理重点措施包括:关注高发人群、细胞因子释放综合征症状、神经系统症状和体征,早期识别患者;做好患者神经精神症状管理、细胞因子释放综合征症状护理及用药等急救护理来保证患者安全;对患者及家属提供专业的心理支持。结果 2例患者均由昏迷转为清醒,无认知障碍,顺利出院。结论 通过对患者的早期识别,有效的神经精神症状管理、细胞因子释放综合征症状护理及用药等急救护理,专业的心理支持等,可保证患者安全,疏导患者及家属不良情绪,促进患者早日康复出院。

关键词

CAR-T / 免疫效应细胞相关神经毒性综合征 / 护理

引用本文

导出引用
阮海涛, 张姿怡, 周丽, 徐丽. 2例白血病患者行嵌合抗原受体T细胞治疗合并严重神经毒性的护理[J]. 护理学报. 2022, 29(12): 67-69 https://doi.org/10.16460/j.issn1008-9969.2022.12.067
RUAN Hai-tao, ZHANG Zi-yi, ZHOU Li, XU Li. Nursing of Leukemia Patients Undergoing Chimeric Antigen Receptor T-cell Therapy with Severe Neurotoxicity: A 2-case Study[J]. Journal of Nursing. 2022, 29(12): 67-69 https://doi.org/10.16460/j.issn1008-9969.2022.12.067
中图分类号: R473.55   

参考文献

[1] Pehlivan KC, Duncan BB, Lee DW.CAR-T Cell Therapy for Acute Lymphoblastic Leukemia:Transforming the Treatment of Relapsed and Refractory Disease[J]. Curr Hematol Malig Rep, 2018, 13(5):396-406.DOI:10.1007/s11899-018-0470-x.
[2] Lee Dw, Santomasso Bd, Locke Fl, et al.ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J].Biol Blood Marrow Transplant,2019,25(4):625-638.DOI:10.1016/j.bbmt.2018.12.758.
[3] Gauthier J, Turtle C J.Insights Into Cytokine Release Syndrome and Neurotoxicity after CD19-specific CAR-T Cell Therapy[J].Curr Res Transl Med,2018,66(2):50-52.DOI:10.1016/j.retram.2018.03.003.
[4] Wang ZG, Han WD.Biomarkers of Cytokine Release Syndrome and Neurotoxicity Related to CAR-T Cell Therapy[J].Biomark Res,2018,6(1):1-10.DOI:10.1186/s40364-018-0116-0.
[5] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学志,2016,37(10):837-845.DOI:10.3760/cma.j.issn.0253-2727.2016.10.002.
[6] Neelapu SS, Tummala S, Kebriaei P,et al.Chimeric Antigen Receptor T-Cell Therapy — assessment and Management of Toxicities[J]. Nat Rev Clin Oncol, 2018,15(1):47.DOI:10.1038/nrclinonc.2017.148.
[7] 石亚群,俞妍慧.嵌合抗原受体T细胞治疗致细胞因子释放综合征与神经毒性的现状及展望[J]. 实用医学杂志,2021,37(2):268-271. DOI:10.3969/j.issn.1006-5725.2021.02.027.
[8] Zhang LN, Song YP, Liu DL.CD19 CAR-T Cell Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: Factors Affecting Toxicities and Long-term Efficacies[J]. J Hematol Oncol,2018,11(1):1-5.DOI:10.1186/s13045-018-0593-5.
[9] Gust J, Taraseviciute A, Turtle CJ.Neurotoxicity Associated with CD19 - targeted CAR-T Cell Therapies[J].CNS Drugs,2018,32(12):1091-1101.DOI:10.1007/s40263-018-0582-9.
[10] Dholaria BR, Bachmeier CA, Locke F.Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities[J].Bio Drugs,2019,33(1):45-60. DOI:10.1007/s40259-018-0324-z.
[11] Hayden PJ, Roddie C, Bader P, et al.Management of Adults and Children Receiving Car T-Cell Therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol,2022,33(3):259-275. DOI:10.1016/j.annonc.2021.12.003.

基金

华中科技大学同济医学院附属同济医院科研基金项目(2013C021)

PDF(450 KB)

Accesses

Citation

Detail

段落导航
相关文章

/